Connect with a sales representative
Now Approved for CIDP

In adults with chronic inflammatory demyelinating polyneuropathy

Learn about Hizentra for CIDP

References

  1. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734-745.
  2. Jolles S, Borte M, Nelson R, et al. Long-term efficacy, safety, and tolerability of Hizentra for treatment of primary immunodeficiency disease. Clin Immunol. 2014;150(2):161-169.
  3. Data on File. Available from CSL Behring as DOF HIZ-003.
  4. Wasserman RL, Melamed I, Nelson RP Jr, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50(6):405-414.
  5. US Department of Health and Human Services, Centers for Medicare & Medicaid Services. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM); 2016;616-617.
  6. American Medical Association. Medicine/hydration, therapeutic, prophylactic, diagnostic injections and infusions, and chemotherapy. In: American Medical Association, ed. CPT 2016. Chicago, IL: American Medical Association; 2016:650-651.
  7. HCPCS Level II Expert. In: American Academy of Professional Coders. Salt Lake City, Utah: AAPC; 2016.
  8. Murphy E, Burton J, Riley P. Nursing approaches to a novel subcutaneous immunoglobulin therapy. Infusion. 2007;13:1-8.
  9. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35-46.
You are now leaving the current website.

Do you want to continue?

No Yes